With numerous adaptive signal strategies to choose from and the ever-increasing cost of deploying new technologies, transportation professionals need to carefully determine the optimal locations of specific adaptive signal control strategies to maximize their benefits. An interoperable decision support system that not only recommends the best network location for deployment but also provides a seamless data exchange between various data sources will be extremely helpful. The development of a prototype geographic information system– (GIS-) based decision support system (DSS) to address some of these issues is presented. A novel software bridge is implemented to ensure data exchange between the most widely used traffic signal optimization and analysis software, Synchro and the developed GIS-based prototype, the Rutgers Adaptive Signal Control Selection (RASCS) DSS. Integrated modules of this unique GIS-based DSS tool—a macroscopic simulator, a rule-based expert system built up by using various sources, and a benefit–cost analysis module—are then described in detail. Case studies that make use of the developed tool also are presented.

No abstract

Background Right ventricular failure is associated with increased morbidity and mortality. The ProtekDuo (Livanova, Uk) is a dual‐lumen cannula that allows for percutaneous right ventricular support and may be connected to a centrifugal blood pump such as the TandemHeart or LifeSparc (Livanova, UK). This systematic review aims to evaluate the safety and efficacy of ProtekDuo right ventricular support and evaluate potential clinical variables that can influence outcomes. Methods PubMed, MEDLINE, SCOPUS, EMBASE, and the Cochrane Library were systematically searched. Studies meeting inclusion criteria, where ProtekDuo was used as the right ventricular assist device with reported numerical death counts for mortality as outcome measures. The primary endpoints were in‐hospital 30‐day and 1‐year mortality rates. Secondary endpoints included ICU length of stay, conversion rates to surgical RVADs, ProtekDuo wean rates, duration of use of ProtekDuo, and adverse event rates. Results Of 49 studies reviewed, 7 met inclusion criteria with study periods between October 2014 and November 2019. ProtekDuo was utilized due to RV failure post‐LVAD insertion in 64.8% (68/105) of patients. In‐hospital mortality, 30‐day mortality, and 1‐year mortality ranged between 9%–46%, 15%–40%, and 19%–40%, respectively. Weaning from ProtekDuo and conversion to surgical RVAD ranged between 24%–91% and 11%–35%, respectively. The ICU stay average ranged from 15.8 to 36 days and ProtekDuo mean support duration ranged from 10.5 to 58 days. Conclusion The ProtekDuo cannula is increasingly utilized as a right ventricular support device. Despite the sparse retrospective data available with variable patient characteristics and study design, percutaneous RV mechanical support via ProtekDuo cannula is a safe and feasible option.

No abstract

No abstract